Latest Osteoporosis Injections in 2026: What to Know

Osteoporosis injections have advanced steadily over the last few years, and 2026 brings important updates on what’s new and what still works.

This guide breaks down the latest four injection options, how they compare to traditional therapies, and how to choose the right plan with your clinician.

Regulatory approvals and availability can vary by country, so confirm local status and coverage. For the most current practice guidance, check trusted sources such as the Endocrine Society and the Bone Health & Osteoporosis Foundation’s clinician guide (BHOF).

The 4 latest osteoporosis injections in 2026

“Latest” here reflects the newest approvals, recently broadened availability (including biosimilars), and the most up-to-date injectable options widely used in 2026. Not every product is brand-new, but these are the key injections shaping care right now.

Always discuss the risks, benefits, and sequencing plan with a specialist—especially if you have very high fracture risk, prior fractures, or complex medical history. Access and coverage can differ across health systems around the world.

1) Denosumab biosimilar (Jubbonti; denosumab-bbdz)

What it is: A biosimilar to Prolia (denosumab), approved in the U.S. in 2024 and expanding in availability thereafter. As a biosimilar, it has no clinically meaningful differences in safety or effectiveness compared with the reference product. See the FDA announcement on first denosumab biosimilars and the manufacturer’s update (FDA; Sandoz).

How it’s given: 60 mg subcutaneous injection every 6 months, typically in a clinic.

Why it matters in 2026: Biosimilars can expand access and may lower costs while maintaining outcomes demonstrated by denosumab (vertebral and hip fracture risk reduction). Importantly, stopping denosumab without a follow-on antiresorptive can cause rapid bone loss and rebound vertebral fractures—plan an “exit strategy.” Review evidence on discontinuation risks (review).

Best for: Postmenopausal women and men at high fracture risk who need potent antiresorptive therapy or have GI intolerance to oral bisphosphonates.

Watch-outs: Hypocalcemia (ensure adequate calcium/vitamin D), rare osteonecrosis of the jaw (ONJ) and atypical femoral fracture risks (shared with potent antiresorptives); transition to another agent if stopping.

2) Romosozumab (Evenity)

What it is: A monoclonal antibody to sclerostin with a dual effect—builds bone and slows bone breakdown. It remains the newest anabolic biologic in broad use. Label and data are detailed in prescribing info and key trials (FDA label; ARCH; FRAME).

How it’s given: Two consecutive subcutaneous injections once monthly for 12 months total.

Why it matters in 2026: Delivers rapid bone mineral density (BMD) gains and substantial vertebral fracture risk reductions within a year; typically followed by an antiresorptive (e.g., bisphosphonate or denosumab) to maintain gains.

Best for: Very high fracture risk (e.g., multiple vertebral fractures, very low T-scores) where a fast, anabolic start is desired.

Watch-outs: Boxed warning for potential increased risk of MI and stroke—avoid in patients with recent cardiovascular events. Injection is limited to 12 months lifetime.

3) Abaloparatide (Tymlos)

What it is: A parathyroid hormone–related peptide analog that stimulates bone formation. Pivotal trials showed large vertebral fracture risk reductions versus placebo (ACTIVE). Label details are here (FDA label).

How it’s given: Daily subcutaneous self-injection using a pen device, typically for up to 18–24 months total of any PTH/PTHrP anabolic therapy (lifetime limit).

Why it matters in 2026: Offers another anabolic route for patients at high or very high fracture risk, including those unable to access romosozumab or where an alternative anabolic is preferred.

Best for: Patients needing bone-building therapy with flexibility for self-administration at home.

Watch-outs: Transient hypercalcemia, dizziness, orthostatic symptoms; not for patients with certain bone tumors or prior skeletal radiation. Follow with an antiresorptive to preserve gains.

4) Teriparatide (Forteo and generics)

What it is: A recombinant human PTH (1–34) anabolic therapy with long-standing evidence for vertebral and nonvertebral fracture risk reduction. As of 2026, lower-cost generics are widely available in many regions. See label information (FDA label).

How it’s given: Daily subcutaneous self-injection via pen for up to a lifetime total of ~24 months of PTH/PTHrP therapy.

Why it matters in 2026: Remains a cornerstone anabolic option, particularly where affordability or insurance coverage favors a generic teriparatide over other anabolics.

Best for: Very high fracture risk patients who can self-inject and wish to maximize bone formation before transitioning to maintenance therapy.

Watch-outs: Similar precautions to abaloparatide; ensure adequate calcium/vitamin D; plan timely transition to an antiresorptive to retain BMD gains.

How do injections compare to traditional treatments?

Traditional first-line therapies have often been oral bisphosphonates (e.g., alendronate, risedronate) due to cost, familiarity, and robust vertebral/hip fracture reduction. Injections can offer distinct advantages:

Potency and speed: Anabolic injections (romosozumab, teriparatide, abaloparatide) build bone quickly—useful in very high risk or imminent fracture scenarios.
Adherence: Twice-yearly denosumab or monthly romosozumab administered in clinic can improve adherence versus weekly oral tablets that require fasting and upright posture.
GI tolerance: Injections bypass esophageal irritation and strict dosing requirements of oral bisphosphonates.
Sequencing power: Anabolic-first then antiresorptive maintenance often yields greater, more durable BMD and fracture benefits than antiresorptive-only starts (supported in guidelines: NOGG; Endocrine Society).

That said, injections also have considerations:

Cost and coverage: Biologics and anabolics are typically costlier; biosimilars can help, but insurance rules vary.
Clinic dependence: Some require in-clinic administration and monitoring.
Safety profiles: Romosozumab’s cardiovascular warning; denosumab rebound risk on discontinuation (review); rare ONJ/atypical femoral fractures with potent antiresorptives (ADA summary).

How to choose the right treatment in 2026

Work with your clinician to personalize therapy. A practical framework:

Assess fracture risk: Combine BMD (DXA) with clinical risks and tools like FRAX. Prior fragility fracture, very low T-scores, or glucocorticoid use often signals need for more potent or anabolic therapy.
Match mechanism to need:
- Very high risk/imminent risk: Start anabolic (romosozumab, abaloparatide, teriparatide), then switch to antiresorptive.
- High risk, not very high: Antiresorptive (denosumab or bisphosphonate) may be appropriate, with escalation if needed.
Mind comorbidities: Avoid romosozumab in recent MI/stroke; consider denosumab when eGFR is low (bisphosphonates are contraindicated with severely reduced renal function—check labels); ensure calcium/vitamin D repletion to prevent hypocalcemia.
Plan the sequence:
- After an anabolic: Transition to an antiresorptive to preserve gains (guideline-supported: Endocrine Society).
- After denosumab: Do not simply stop; give a bisphosphonate or suitable alternative to mitigate rebound (review).
Balance practicality and cost: Clinic vs home injections, device comfort, travel, and insurance coverage. Biosimilars and generics can improve affordability.
Set monitoring cadence: DXA every 1–2 years, sooner if therapy changes; consider bone turnover markers to gauge response (per BHOF guide).

Safety, side effects, and practical tips

Calcium and vitamin D: Ensure consistent intake to support all therapies (BHOF patient resource).
Dental health: Complete needed dental work and maintain oral hygiene before and during potent antiresorptives; discuss ONJ risk with your provider (ADA).
Injection technique and storage: Review pen training for daily anabolics; store and travel with pens per the label. Clinic-administered injections simplify this for many patients.
Lifestyle matters: Fall prevention, strength and balance training, adequate protein, and limiting tobacco/alcohol remain foundational, regardless of medication choice.
DXA follow-up: Track progress and adjust if BMD plateaus or fractures occur despite therapy (DXA basics).
Pregnancy and special populations: Many osteoporosis drugs are not recommended during pregnancy; consult specialists for premenopausal women, men with secondary causes, or those on long-term glucocorticoids.

Key takeaways

In 2026, the most impactful injection updates include the expansion of denosumab biosimilars (e.g., Jubbonti), plus continued use of romosozumab, abaloparatide, and teriparatide for the right patients.
Anabolic-first strategies, followed by antiresorptive maintenance, often deliver the biggest and most durable gains in high-risk patients.
Plan ahead: never stop denosumab without a transition plan; limit romosozumab to 12 months and PTH/PTHrP anabolics to about 24 months lifetime.
Personalize choices to fracture risk, comorbidities, adherence needs, and cost/coverage—and check the latest guidelines as availability evolves.

As always, use this overview as a starting point for a detailed, individualized discussion with your healthcare provider.